Patritumab
Based on 2 publication(s) in Google Scholar
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.28%
- CAS No.: 1262787-83-6
- Masse moléculaire:146.86 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Patritumab
More
Customer Validation & Images
-
WB
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Human IgG1(K214R) kappa
Human
ERBB3/HER3
Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis[1].
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells[1].
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DiFi-HRG cells
-
Concentration:10 μg/mL
-
Incubation Time:6 hours
-
Result:Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)[1]
-
Dosage:1 mg/body
-
Administration:Intraperitoneal injection; twice a week for 4 weeks
-
Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.
Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1×106 MCF-7 cells labelling HER3 (red) with Patritumab (HY-P99275). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1(K214R) kappa Isotype Control (HY-P99995, blue) was used as the isotype control. -
Immobilized Human HER3/ERBB3 Protein (ECD, His Tag) can bind Patritumab. The EC50 for this effect is 1.41 ng/mL. -
Loaded Patritumab on AHC2 biosensor, can bind HER3 Protein, Human (HEK293, His, HY-P72625) with an affinity constant of 1.804E-09 M as determined in BLI assay.
Chemical Information
-
CAS No. 1262787-83-6
-
Appearance Liquid
-
Masse moléculaire 146.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Patritumab]
-
Synonyms
AMG-888; U3-1287
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Clin Cancer Res
ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature. [Abstract]2024 Apr 15;30(8):1530-1543. PMID: 38306015
Patritumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2024 Apr 15;30(8):1530-1543. [Abstract]
Patritumab (10 μM; 2 h) reduced pHER3 after NRG1 stimulation (100 ng/mL; 15 min) in CWR-R1 cells.
-
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz